217 related articles for article (PubMed ID: 34013757)
1. Pooled platelet concentrates provide a small benefit over single-donor platelets for patients with platelet refractoriness of any etiology.
Chu YH; Rose WN; Nawrot W; Raife TJ
J Int Med Res; 2021 May; 49(5):3000605211016748. PubMed ID: 34013757
[TBL] [Abstract][Full Text] [Related]
2. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
3. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
Hitzler WE
Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
[TBL] [Abstract][Full Text] [Related]
4. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
6. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
Heal JM; Blumberg N; Masel D
Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
[TBL] [Abstract][Full Text] [Related]
8. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
9. HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets.
O'Rafferty C; Rooney G; Hagan R; Woolfson M; O'Donghaile D; Fitzgerald J
Transfus Med; 2017 Oct; 27 Suppl 5():369-374. PubMed ID: 28393455
[TBL] [Abstract][Full Text] [Related]
10. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
Gavva C; Barroso J; Gernsheimer T; Metcalf RA; Warner P; Pagano MB
Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Human Leucocyte Antigen Mediated Platelet Transfusion Refractoriness and Platelet Crossmatching Assay in Patients with Hematologic Disorders.
Neanaey WA; Deghady AA; Nafea DA; Fahmy NM; Gouda AM
Oman Med J; 2022 Jul; 37(4):e402. PubMed ID: 35915764
[TBL] [Abstract][Full Text] [Related]
12. Platelet transfusion. Current techniques, remaining problems, and future prospects.
Herman JH; Kamel HT
Am J Pediatr Hematol Oncol; 1987; 9(3):272-86. PubMed ID: 3314551
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates.
McFarland JG; Anderson AJ; Slichter SJ
Br J Haematol; 1989 Nov; 73(3):380-6. PubMed ID: 2605125
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets.
Karafin MS; Schumacher C; Zhang J; Simpson P; Johnson ST; Pierce KL
Transfusion; 2021 Aug; 61(8):2307-2316. PubMed ID: 34075590
[TBL] [Abstract][Full Text] [Related]
15. High-yield platelet concentrates attainable by continuous quality improvement reduce platelet transfusion cost and donor exposure.
Kelley DL; Fegan RL; Ng AT; Kennedy MK; Blanda E; Chambers LA; Kennedy MS; Lasky LC
Transfusion; 1997 May; 37(5):482-6. PubMed ID: 9149771
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
[TBL] [Abstract][Full Text] [Related]
17. [Refractory effect and alloimmunization after transfusion of thrombocytes].
Volkova RI; Agranenko VA
Gematol Transfuziol; 1992 Feb; 37(2):16-21. PubMed ID: 1426903
[TBL] [Abstract][Full Text] [Related]
18. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
Levy L; Woodfield DG
N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
[TBL] [Abstract][Full Text] [Related]
19. A mini-review on platelet refractoriness.
Rebulla P
Haematologica; 2005 Feb; 90(2):247-53. PubMed ID: 15710579
[TBL] [Abstract][Full Text] [Related]
20. Use of Human Leukocyte Antigen (HLA)-Incompatible Platelet Units in HLA Platelet-Refractory Patients With Limited Number of or Low-Level HLA Donor-Specific Antibodies Results in Permissive Transfusions.
Sullivan JC; Peña JR
Arch Pathol Lab Med; 2022 Oct; 146(10):1243-1251. PubMed ID: 35171984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
